Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women

Fertility and Sterility

Volumn 95, Issue 3, 2011, Pages 1188-1191

  Murkes, Daniel ^a   Conner, Peter ^b   Leifland, Karin ^c   Tani, Edneia ^b   Beliard, Aude ^d   Lundström, Eva ^b   Söderqvist, Gunnar ^b  

^a Sodertalje Hospital   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

bcl 2 protein; HT; micronized progesterone; normal breast tissue; Percutaneous estradiol; proliferation

Indexed keywords

BAG 1 PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; MICRONIZED P; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CELL; CELL PROLIFERATION; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOHISTOCHEMISTRY; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; BIOPSY; BREAST; BREAST NEOPLASMS; CELL DIVISION; CONTRACEPTIVE AGENTS, FEMALE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS;

EID: 79951951986     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.09.062     Document Type: Article

References (30)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33. (Pubitemid 34761611)
2. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
3. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23. (Pubitemid 32109768)
4. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-58. (Pubitemid 35449180)
5. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-16. (Pubitemid 351670642)
6. Chlebowski RT, Hendrix SL, Langer RD, StefanickML,Gass M, Lane D, et al., for theWHI investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. J Am Med Assoc 2003;289:3242-53.
7. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9. (Pubitemid 29091853)
8. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-80. (Pubitemid 17173057)
9. Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-8. (Pubitemid 127780760)
10. Isaksson E, von Schoultz E, Odlind V, Söderqvist G, Csemiczky G, Carlström K, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-9. (Pubitemid 32193620)
11. Lundström E, Söderqvist G, Svane G, Azavedo E, Olofsson M, Skoog L, et al. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study. Fertil Steril 2006;85:989-95.
12. Conner P, Christow A, Kersemaekers W, Söderqvist G, Skoog L, Carlström K, et al. A comparative study on breast cell proliferation during hormone replacement therapy. Effects of tibolone and combined estrogen-progestogen treatment. Climacteric 2004;7:50-8.
13. Preston-Martin S, Pike MP, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
14. Conner P, Register TC, Skoog L, Tani E, von Schoultz B, Cline JM. Expression of P53 and markers of apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. Am J Obstet Gynecol 2005;193:58-63. (Pubitemid 40991826)
15. Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617-23. (Pubitemid 38376119)
16. Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9. (Pubitemid 28193936)
17. Fournier S, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies. Breast Cancer Res Treat 2008;107:103-11. (Pubitemid 350179584)
18. Gerdes J, Li L, Schlueter C, Duchrow M, Whienberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
19. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000;65:593-8.
20. Södergård R, Bäckström T, Shanbag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17b to plasma proteins at body temperature. J Steroid Biochem 1982;18:801-4.
21. Hofling M, Linden-Hirschberg A, Skoog L, Tani E, Hägerström T, von Schoultz B. Testosterone inhibits estrogen/progestogen induced breast cell proliferation in postmenopausal women. Menopause 2007;14:183-90. (Pubitemid 46673468)
22. Conner P, Söderqvist G, Skoog L, Gräser T, Walter F, Tani E, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration biopsy. Breast Cancer Res Treat 2003;78:159-65.
23. Wood CE, Register T, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-34. (Pubitemid 46115419)
24. Conner P, Skoog L, Söderqvist G. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle aspiration cytology. Climacteric 2001;4:7-12. (Pubitemid 32448482)
25. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138-43.
26. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone therapy use and variations in the risk of breast cancer. Br J Obstet Gynaecol 2008;115:169-75. (Pubitemid 350233601)
27. Conner P, Lundström E, von Schoultz B. Breast cancer and hormonal therapy. Clin Obstet Gynecol 2008;51:592-606.
28. Willet WC, Colditz G, Stampfer M. Postmenopausal estrogens - opposed, unopposed, or none of the above. J Am Med Assoc 2000;283:534-5. (Pubitemid 30062873)
29. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cell in women with pre-existing breast cancers: a hypothesis. J Clin EndocrinolMetab 2008;93:3295-8.
30. Engman M, Skoog L, Söderqvist G, Gemzell K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 2008;23:2072-9.